Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025)

Heron Therapeutics (HRTX) has 5 years of Amortization of Deferred Charges data on file, last reported at -$35000.0 in Q4 2025.

• Quarterly Amortization of Deferred Charges fell 166.04% year-over-year to -$35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $118000.0 (down 61.31% YoY) and the FY2025 annual result came in at $73000.0, down 65.24% from the prior year.
• Amortization of Deferred Charges fell to -$35000.0 in Q4 2025, from $100000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $100000.0 in Q3 2023 to a low of -$35000.0 in Q4 2025.
• A 5-year average of $55333.3 and a median of $51000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 163.16% — and 2025, when it slumped 166.04%.
• Tracing HRTX's Amortization of Deferred Charges over 5 years: stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then grew by 2.0% to $51000.0 in 2023, then increased by 3.92% to $53000.0 in 2024, then tumbled by 166.04% to -$35000.0 in 2025.
• The last three Amortization of Deferred Charges figures came in at -$35000.0 (Q4 2025), $100000.0 (Q2 2025), and $53000.0 (Q1 2025), per Business Quant data.